These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 18564448)

  • 1. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases for candidates for therapy with tumor necrosis factor alpha inhibitors--March 2008 update.
    Eurico Fonseca J; Lucas H; Canhão H; Duarte R; José Santos M; Villar M; Faustino A; Raymundo E;
    Rev Port Pneumol; 2008; 14(2):271-83. PubMed ID: 18564448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update.
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E
    Acta Reumatol Port; 2008; 33(1):77-85. PubMed ID: 18344925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors - March 2008 update.
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E
    Rev Port Pneumol; 2008; 14(2):271-83. PubMed ID: 25966834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflammatory joint diseases proposed for treatment with tumour necrosis factor alpha antagonist drugs].
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
    Rev Port Pneumol; 2006; 12(5):603-13. PubMed ID: 17117328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recommendations for the diagnosis and treatment of latent and active tuberculosis in patients with inflammatory joint diseases treated with tumour necrosis factor alpha inhibitors].
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
    Acta Reumatol Port; 2006; 31(3):237-45. PubMed ID: 17094335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.
    Calzada-Hernández J; Anton-López J; Bou-Torrent R; Iglesias-Jiménez E; Ricart-Campos S; Martín de Carpi J; ; Torrente-Segarra V; Sánchez-Manubens J; Giménez-Roca C; Rozas-Quesada L; Juncosa-Morros MT; Fortuny C; Noguera-Julian A
    Pediatr Rheumatol Online J; 2015 Dec; 13():54. PubMed ID: 26635208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Update of the guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
    Balbir-Gurman A; Lidgi M; Elkayam O
    Harefuah; 2014 Jun; 153(6):359-61, 366. PubMed ID: 25095612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.
    Lee H; Park HY; Jeon K; Jeong BH; Hwang JW; Lee J; Cha HS; Koh EM; Kang ES; Koh WJ
    PLoS One; 2015; 10(3):e0119260. PubMed ID: 25746854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
    Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis.
    Martin J; Walsh C; Gibbs A; McDonnell T; Fearon U; Keane J; Codd MB; Dodd J; Veale D; Fitzgerald O; Bresnihan B
    Ann Rheum Dis; 2010 Jan; 69(1):181-5. PubMed ID: 19176545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents.
    Klein M; Jarosová K; Forejtová S; Bečvář R; Sedová L; Pavelka K; Simková G; Svobodová R; Hviscová K; Mann H; Půtová I; Vencovský J
    Clin Exp Rheumatol; 2013; 31(1):111-7. PubMed ID: 23101473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
    Gómez-Reino JJ; Carmona L; Angel Descalzo M;
    Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents.
    Garziera G; Morsch ALB; Otesbelgue F; Staub FL; Palominos PE; Brenol CV; Silva DR
    Clin Rheumatol; 2017 Aug; 36(8):1891-1896. PubMed ID: 28589321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
    Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
    J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for latent tuberculosis in anti-TNF-α candidate patients in a high tuberculosis incidence setting.
    Saidenberg-Kermanac'h N; Semerano L; Naccache JM; Brauner M; Falgarone G; Dumont-Fischer D; Guillot X; Valeyre D; Boissier MC
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1307-14. PubMed ID: 22863801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment.
    Jung YJ; Lyu J; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1300-6. PubMed ID: 22863375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
    Sato S; Nagai H
    Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Screening for tuberculosis infection prior to medical therapy].
    Ravn P
    Ugeskr Laeger; 2011 Mar; 173(12):893-6. PubMed ID: 21419060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.